ImmunoRestoration, Inc. was formed in 2016 to commercialize groundbreaking immunotherapeutic cancer vaccine research begun in 2004 at the University of Pennsylvania. The decision to pursue this opportunity was made after carefully evaluating data associated with pre-clinical research and studies involving more than 100 patients. Late in 2017, the company acquired the global exclusive rights to bring this technology to market and is now poised to help usher in a new era of precision, patient-centric cancer treatment.
ImmunoRestoration’s novel platform vaccine helps patients fight breast cancer by rejuvenating their own immune system. The vaccine-restored immune response then acts synergistically with other treatments to enable the body to heal itself.
While we strive to attain a leadership position with breast cancer assessment and treatment, our broader goal is to collaborate with the medical community worldwide to save lives. During our exhaustive clinical research efforts, we are observing amazing results today in our labs with immunotherapy that can benefit humanity as we minimize the debilitating effects of breast cancer and other cancers globally.
More than 12 years ago, researchers at the University of Pennsylvania began work on DC1 vaccines for the treatment of Ductal Carcinoma In Situ. This early work demonstrated that the use of dendritic cells in a vaccine can stop a type of regulatory white blood cell that shields tumors from immune attack. This work helped define the principles for producing investigational dendritic cell therapies in DCIS and other cancers.